There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > MMP-2


MMP-2 Molecule Information

Name:Matrix metalloproteinase-2
Target Synonym:PEX;TBE-1;MMP-2;Gelatinase A;CLG4A;MMP2;72 kDa type IV collagenase;72 kDa gelatinase;Matrix metalloproteinase-2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:14
Lastest Research Phase:NDA Filing

MMP-2 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
MM2-H5225 Human Human MMP-2 Protein, His Tag

MMP-2 Molecule Synonym Name


MMP-2 Molecule Background

Matrix metalloproteinase-2 (MMP-2) is also known as 72 kDa type IV collagenase, 72 kDa gelatinase, Gelatinase A and CLG4A, which belongs to the peptidase M10A family. MMP-2 / CLG4A contains 3 fibronectin type-II domains and 4 hemopexin-like domains. MMP-2 is produced by normal skin fibroblasts. MMP-2 cleaves the collagen-like sequence Pro-Gln-Gly-|-Ile-Ala-Gly-Gln. MMP2 involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. PEX, the C-terminal non-catalytic fragment of MMP2, posseses anti-angiogenic and anti-tumor properties and inhibits cell migration and cell adhesion to FGF2 and vitronectin.

MMP-2 References

MMP-2 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Abametapir BRN-0123183; DFD-11; HA-44; Ha44 Gel Approved Hatchtech XEGLYZE fda DR REDDYS LABS SA 2020-07-24 Pediculosis Details

MMP-2 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
131-I-Chlorotoxin TM-601-I-131; 131-I-TM-601 Phase Ⅱ TransMolecular, Morphotek Glioma Details
AQU-005 AQU-005; NMAQU-005; NM-AQU-005 Phase Ⅰ Aquilus Pharmaceuticals, NeuroMax Neuropathic pain Details
ABT-518 ABT 518 Phase Ⅰ Abbvie Solid tumours Details
SD-7300 Phase Ⅰ Pfizer Solid tumours Details
PG-116800 PG-116800; PG-530742; PGE-7113313,PG116800; PG530742; PGE7113313,PG 116800; PG 530742; PGE 7113313 Phase Ⅱ Procter & Gamble Osteoarthritis (OA), Heart failure, Myocardial infarction (MI) Details
Incyclinide CMT-3; COL-3; NSC-683551 Phase Ⅱ Galderma Acne, Rosacea Details
XL-784 XL-784,XL784 Phase Ⅱ Exelixis, Symphony Evolution Diabetic nephropathy Details
S-3304 S-3304 Phase Ⅱ Shionogi Solid tumours Details
Tanomastat BAY-12-9566 Phase Ⅲ Bayer Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Ovarian cancer, Pancreatic cancer Details
AE-941 AE-941; NSC-706456 Phase Ⅲ AEterna Zentaris, Ferrer, Pfizer, National Cancer Institute, Alcon Non small cell lung cancer (NSCLC), Renal carcinoma Details
PNU-248686A PNU-248686A Phase Ⅰ Pfizer Solid tumours Details
RS-130830 RS-130830; CTS-1027; RO-1130830,RS130830,CTS1027,RO1130830 Phase Ⅱ Roche, Conatus Pharmaceutical Arthritis, HCV infection Details
Rebimastat BMS-275291; D-2163 Phase Ⅲ Celltech, Bristol-Myers Squibb Non small cell lung cancer (NSCLC) Details

This web search service is supported by Google Inc.